全文获取类型
收费全文 | 313篇 |
免费 | 33篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 5篇 |
妇产科学 | 4篇 |
基础医学 | 23篇 |
临床医学 | 30篇 |
内科学 | 79篇 |
皮肤病学 | 2篇 |
神经病学 | 23篇 |
特种医学 | 9篇 |
外科学 | 97篇 |
综合类 | 18篇 |
一般理论 | 1篇 |
预防医学 | 26篇 |
眼科学 | 3篇 |
药学 | 14篇 |
中国医学 | 1篇 |
肿瘤学 | 7篇 |
出版年
2024年 | 3篇 |
2023年 | 1篇 |
2022年 | 10篇 |
2021年 | 24篇 |
2020年 | 11篇 |
2019年 | 16篇 |
2018年 | 16篇 |
2017年 | 11篇 |
2016年 | 2篇 |
2015年 | 19篇 |
2014年 | 17篇 |
2013年 | 14篇 |
2012年 | 22篇 |
2011年 | 25篇 |
2010年 | 8篇 |
2009年 | 14篇 |
2008年 | 18篇 |
2007年 | 13篇 |
2006年 | 15篇 |
2005年 | 12篇 |
2004年 | 9篇 |
2003年 | 12篇 |
2002年 | 12篇 |
2001年 | 6篇 |
2000年 | 2篇 |
1999年 | 2篇 |
1998年 | 2篇 |
1997年 | 1篇 |
1994年 | 1篇 |
1992年 | 4篇 |
1991年 | 1篇 |
1990年 | 3篇 |
1989年 | 2篇 |
1986年 | 2篇 |
1985年 | 3篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1982年 | 3篇 |
1980年 | 1篇 |
1979年 | 3篇 |
1978年 | 1篇 |
1965年 | 1篇 |
1964年 | 1篇 |
排序方式: 共有346条查询结果,搜索用时 15 毫秒
31.
Dustin T. Rae Jonah D. Hocum Victor Bii H. Joachim Deeg Grant D. Trobridge 《Oncotarget》2015,6(31):30664-30674
Using a novel retroviral shuttle vector approach we identified genes that collaborate with a patient derived RUNX1 (AML1) mutant. RUNX1 mutations occurs in 40% of myelodysplastic syndromes (MDS). MDS are a group of hematopoietic stem cell disorders that are characterized by dysplasia that often progress to acute myeloid leukemia (AML). Our goal was to identify genes dysregulated by vector-mediated genotoxicity that may collaborate with the RUNX1 mutant (D171N). D171N expressing cells have a survival and engraftment disadvantage and require additional genetic lesions to survive and persist. By dysregulating genes near the integrated vector provirus, the shuttle vector can promote transformation of D171N cells and tag the nearby genes that collaborate with D171N. In our approach, a gammaretroviral shuttle vector that expresses D171N is used to transduce CD105+, Sca-1+ mouse bone marrow. Mutagenized cells are expanded in liquid culture and vector integration sites from surviving cells are then identified using a retroviral shuttle vector approach. We repeatedly recovered integrated vector proviruses near genes (Itpkb, Ccdc12, and Nbeal2). To assess the prognostic significance of the genes identified we examined differential expression, overall survival, and relapse free survival of AML patients with alteration in the genes identified using The Cancer Genome Atlas (TCGA) AML data set. We found that ITPKB functions as an independent factor for poor prognoses and RUNX1 mutations in conjunction with ITPKB, CCDC12, and NBEAL2 have prognostic potential in AML. 相似文献
32.
Terrault NA Roland ME Schiano T Dove L Wong MT Poordad F Ragni MV Barin B Simon D Olthoff KM Johnson L Stosor V Jayaweera D Fung J Sherman KE Subramanian A Millis JM Slakey D Berg CL Carlson L Ferrell L Stablein DM Odim J Fox L Stock PG;Solid Organ Transplantation in HIV: Multi-Site Study Investigators 《Liver transplantation》2012,18(6):716-726
Hepatitis C virus (HCV) is a controversial indication for liver transplantation (LT) in human immunodeficiency virus (HIV)-infected patients because of reportedly poor outcomes. This prospective, multicenter US cohort study compared patient and graft survival for 89 HCV/HIV-coinfected patients and 2 control groups: 235 HCV-monoinfected LT controls and all US transplant recipients who were 65 years old or older. The 3-year patient and graft survival rates were 60% [95% confidence interval (CI) = 47%-71%] and 53% (95% CI = 40%-64%) for the HCV/HIV patients and 79% (95% CI = 72%-84%) and 74% (95% CI = 66%-79%) for the HCV-infected recipients (P < 0.001 for both), and HIV infection was the only factor significantly associated with reduced patient and graft survival. Among the HCV/HIV patients, older donor age [hazard ratio (HR) = 1.3 per decade], combined kidney-liver transplantation (HR = 3.8), an anti-HCV-positive donor (HR = 2.5), and a body mass index < 21 kg/m(2) (HR = 3.2) were independent predictors of graft loss. For the patients without the last 3 factors, the patient and graft survival rates were similar to those for US LT recipients. The 3-year incidence of treated acute rejection was 1.6-fold higher for the HCV/HIV patients versus the HCV patients (39% versus 24%, log rank P = 0.02), but the cumulative rates of severe HCV disease at 3 years were not significantly different (29% versus 23%, P = 0.21). In conclusion, patient and graft survival rates are lower for HCV/HIV-coinfected LT patients versus HCV-monoinfected LT patients. Importantly, the rates of treated acute rejection (but not the rates of HCV disease severity) are significantly higher for HCV/HIV-coinfected recipients versus HCV-infected recipients. Our results indicate that HCV per se is not a contraindication to LT in HIV patients, but recipient and donor selection and the management of acute rejection strongly influence outcomes. 相似文献
33.
34.
Jonah A. Hoyt BS Emily Cozzi PhD David A. D'Alessio MD Chris C. Thompson MD Vanita R. Aroda MD 《Diabetes, obesity & metabolism》2024,26(6):2017-2028
Affecting 5%–10% of the world population, type 2 diabetes (T2DM) is firmly established as one of the major health burdens of modern society. People with T2DM require long-term therapies to reduce blood glucose, an approach that can mitigate the vascular complications. However, fewer than half of those living with T2DM reach their glycaemic targets despite the availability of multiple oral and injectable medications. Adherence and access to medications are major barriers contributing to suboptimal diabetes treatment. The gastrointestinal tract has recently emerged as a target for treating T2DM and altering the underlying disease course. Preclinical and clinical analyses have elucidated changes in the mucosal layer of the duodenum potentially caused by dietary excess and obesity, which seem to be prevalent among individuals with metabolic disease. Supporting these findings, gastric bypass, a surgical procedure which removes the duodenum from the intestinal nutrient flow, has remarkable effects that improve, and often cause remission of, diabetes. From this perspective, we explore the rationale for targeting the duodenum with duodenal mucosal resurfacing (DMR). We examine the underlying physiology of the duodenum and its emerging role in T2DM pathogenesis, the rationale for targeting the duodenum by DMR as a potential treatment for T2DM, and current data surrounding DMR. Importantly, DMR has been demonstrated to change mucosal abnormalities common in those with obesity and diabetes. Given the multifactorial aetiology of T2DM, understanding proximate contributors to disease pathogenesis opens the door to rethinking therapeutic approaches to T2DM, from symptom management toward disease modification. 相似文献
35.
Matthew L. Romo Allahna L. Esber John Owuoth Jonah Maswai Valentine Sing'oei Michael Iroezindu Emmanuel Bahemana Hannah Kibuuka J. Sean Cavanaugh Neha Shah Julie A. Ake Trevor A. Crowell the AFRICOS Study Group 《HIV medicine》2023,24(10):1066-1074
Objective
We hypothesized that total body weight (TBW) gain after switching antiretroviral therapy (ART) regimen to tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) may negatively impact ART adherence and viral load (VL) and therefore sought to examine these associations.Methods
The ongoing African Cohort Study (AFRICOS) enrols people with HIV at 12 facilities in Kenya, Nigeria, Tanzania and Uganda supported by The US President's Emergency Plan for AIDS Relief. Among ART-experienced participants who switched to TLD, we used multivariable multinomial logistic regression to examine associations between pre−/post-TLD changes in percentage TBW (≥5% gain, <5% change, ≥5% loss) and changes in self-reported ART adherence (0, 1–2, ≥3 days missed doses in past 30 days) and VL [(<50 copies/mL (undetectable), 50–999 copies/mL (detectable, but suppressed), ≥1000 copies/mL (unsuppressed)].Results
Among 1508 participants, median time from starting TLD to follow-up was 9 months (interquartile range: 7–11). Overall, 438 (29.1%) participants experienced a TBW gain ≥5%, which was more common among females than among males (32.2% vs 25.2%, p = 0.005) and participants switching from efavirenz [32.0% vs nevirapine (19.9%) and boosted protease inhibitor (20.0%); p < 0.001]. Compared with a TBW change <5% [950 (63.0%) participants], TBW gain ≥5% was not significantly associated with more days with missed ART doses [adjusted odds ratio (aOR) = 0.77, 95% confidence interval (CI): 0.48–1.23] or VL becoming detectable and/or unsuppressed (aOR = 0.69, 95% CI: 0.41–1.16).Conclusions
Although a substantial proportion of participants experienced weight gain after switching to TLD, we did not identify a significant impact on adherence or virological outcomes. 相似文献36.
37.
38.
Nissreen Mohammad Derek Wong Amy Lum Jonah Lin Julie Ho Cheng-Han Lee Stephen Yip 《Histopathology》2020,76(5):722-730
39.
40.
The primary purpose of this study was to identify predictors of impaired driving among a random sample of Canadian drivers who consume beverage alcohol. A second purpose was to determine if impaired drivers in the general population have characteristics similar to those reported among convicted and accident-involved impaired drivers. Amount of alcohol consumed over the past seven days was found to be the single most powerful predictor of both frequency of drinking-driving and of impaired driving. Impaired drivers differed from moderate-drinking drivers on a number of measures and were characterized by more irresponsible attitudes and higher risk behavior, consistent with findings of other impaired-driver subgroups. It is concluded that impaired driving may be just one behavior which is part of a deviant behavioral syndrome typified by high-risk behaviors. 相似文献